Entwicklung von Livoletide (PWS) wird gestoppt
"The decision to discontinue the PWS program was based on topline data from the pivotal Phase 2b ZEPHYR study which showed that treatment with livoletide did not result in a statistically significant improvement in hyperphagia and food-related behaviors as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) compared to placebo."
- 2019-er Verlust 45 Mio. $ (~11 Mio. $ pro Quartal)
- Cash 65 Mio. $
- EK 60 Mio. $
- Total Assets 75 Mio. $